Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 539

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 2
Chunk 539
---
.

The following table sets forth the names, ages as of February 27, 2025, and certain other information for each of our current directors and executive officers:

NamePosition Held with the Company Date first appointed Age      Gregory D. GorgasPresident, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director April 3, 2017 62Connie Matsui(1)(2)Director, Chairperson of the Board May 2, 2017 71Steven Kelly(1)(3) Director May 2, 2017 59Douglas Blayney, M.D.(2)Director July 31, 2017 74R. Martin Emanuele, Ph. D.(2)Director September 20, 2017 70Greg Reyes, M.D., Ph. D.(3) Director November 30, 2020 71Tamara A. Favorito(1) (3)Director  March 3, 2021  66

_______________ 

(1) Member of the audit committee(2) Member of the corporate governance and nominating committee(3) Member of the compensation committee

Business Experience

The following is a brief account of the education and business experience during at least the past five years of each director and executive officer of our company, indicating the person’s principal occupation during that period, and the name and principal business of the organization in which such occupation and employment were carried out.

Directors

Gregory D. Gorgas was appointed president, chief executive officer, chief financial officer, treasurer, secretary and director of our Company in April 2017. Prior to joining our Company, Mr. Gorgas was Senior Vice President, Commercial, and Corporate Officer at Mast Therapeutics from July 2011 to January 2017 with commercial leadership accountability and business development responsibilities for the hematology, oncology and cardiovascular development programs. In addition, he performed a key role in helping Mast Therapeutics raise over $50M in new capital. From November 2009 to July 2011, Mr. Gorgas was Managing Director at Theragence, Inc., a privately held company he co-founded, that applied proprietary computational intelligence to mine and analyze clinical data. From November 2008 to July 2011, Mr. Gorgas also served as an independent consultant, providing commercial and business development consulting services to pharmaceutical, biotechnology and medical device